Celcuity Inc. (CELC): Price and Financial Metrics

Celcuity Inc. (CELC): $9.40

0.15 (-1.57%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

C

CELC Price/Volume Stats

Current price $9.40 52-week high $14.40
Prev. close $9.55 52-week low $7.50
Day low $9.14 Volume 67,400
Day high $9.74 Avg. volume 76,757
50-day MA $9.83 Dividend yield N/A
200-day MA $10.51 Market Cap 207.65M

CELC Stock Price Chart Interactive Chart >


Celcuity Inc. (CELC) Company Bio


Celcuity LLC, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. It develops CELx tests to diagnose breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is based in Minneapolis, Minnesota.


CELC Latest News Stream


Event/Time News Detail
Loading, please wait...

CELC Latest Social Stream


Loading social stream, please wait...

View Full CELC Social Stream

Latest CELC News From Around the Web

Below are the latest news stories about CELCUITY INC that investors may wish to consider to help them evaluate CELC as an investment opportunity.

The 7 Best Short-Squeeze Stocks to Buy Now: September 2023

Explore the potential of the best short-squeeze stocks to buy now as companies attempt to prove pessimistic traders wrong.

Josh Enomoto on InvestorPlace | September 21, 2023

Celcuity to Host Virtual Science Day for Investors

Leading key opinion leaders to review the treatment landscape in breast and prostate cancer and the importance of targeting the PI3K/mTOR pathway in hormonally driven tumor typesDiscussion of the planned Phase 1b/2 trial for gedatolisib in combination with Nubeqa® (darolutamide) in patients with mCRPCEvent to be webcast from 10:00 a.m. – 12:00 p.m. ET on September 21, 2023 MINNEAPOLIS, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuin

Yahoo | September 7, 2023

7 Short-Squeeze Stocks That Actually Might Make Sense

Although the concept of short-squeeze stocks is one best left for speculators, these ideas have a touch of rationality behind them.

Josh Enomoto on InvestorPlace | September 6, 2023

Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial

MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it has entered into a clinical trial collaboration and supply agreement with Bayer AG for Celcuity’s Phase 1b/2 clinical trial of gedatolisib and Nubeqa® (darolutamide) in patients with metastatic castration resistant prostate cancer (mCRPC). As part of the supply agreement, Bayer will provide Nubeqa to C

Yahoo | August 22, 2023

Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer

- Received FDA clearance of IND for gedatolisib in combination with darolutamide - Virtual Science Day to be held on September 21, 2023 from 10:00 a.m. – 12:00 p.m. ET MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, has been notified by the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) submission has been reviewed, and Celcuity can proceed

Yahoo | August 22, 2023

Read More 'CELC' Stories Here

CELC Price Returns

1-mo -2.29%
3-mo -14.39%
6-mo -8.29%
1-year 1.18%
3-year N/A
5-year -67.32%
YTD -32.91%
2022 6.22%
2021 44.00%
2020 -13.91%
2019 -55.65%
2018 26.60%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!